Pharma Focus Asia

Myriad Genetics and National Cancer Center Hospital East in Japan Partner on Pan-Cancer MRD Monitoring Clinical Trial: SCRUM-MONSTAR-SCREEN-3

Wednesday, February 28, 2024

Myriad Genetics, Inc. (NASDAQ: MYGN), a leading company in genetic testing and precision medicine, has announced a research collaboration with Japan's National Cancer Center Hospital East (NCCHE) to explore the prognostic and predictive potential of molecular residual disease (MRD) testing. This collaboration involves the SCRUM-MONSTAR-SCREEN-3 study, which will utilize Myriad’s ultra-sensitive MRD test, Precise MRD, to monitor circulating tumor DNA (ctDNA) in patients diagnosed with various solid tumor and hematological cancers.

Led by Dr. Takayuki Yoshino of NCCHE, the SCRUM-MONSTAR-SCREEN-3 study aims to leverage multi-omic profiling to devise more tailored treatment approaches across three study cohorts. Approximately 1,200 patients spanning over 20 cancer types will participate in two of these cohorts, undergoing MRD monitoring via Precise MRD. The study's objective is to generate robust prospective clinical evidence supporting the broad applicability of MRD testing across cancer types and different disease severities or stages.

Dr. Yoshino, Deputy Director of NCCHE and Head of the Division for the Promotion of Drug and Diagnostic Development, emphasized the need for an MRD test sensitive enough to detect ctDNA at low levels, particularly for cancers with minimal tumor shedding. He underscored the uniqueness of Myriad's MRD assay in this aspect and highlighted the potential of the SCRUM-MONSTAR-SCREEN-3 study to redefine the landscape of whole-genome sequencing-based MRD projects, paving the way for MRD-guided therapeutic strategies across diverse cancer types.

Myriad Genetics, expressed excitement about collaborating with NCCHE on the SCRUM-MONSTAR-SCREEN-3 study, citing NCCHE's leadership in MRD research. He noted NCCHE's involvement in groundbreaking trials like CIRCULATE-Japan, which includes GALAXY, VEGA, and ALTAIR trials in colorectal cancer patients. Dr. Muzzey emphasized the design of Precise MRD to be highly sensitive across all cancer types and anticipated the study to showcase its efficacy in cancer management.

 

Source: globenewswire.com

magazine-slider-imageMFA + MMA 2024CPHI Chine || PMEC China 2024Asia Healthcare Week 2024Advance DoE WorkshopNitrosamine Advance Workshop 2024CPHI Korea 2024CHEMICAL INDONESIA 2024INALAB 2024 Thermo Scientific - DynaDrive and DynaSpinDigital Health Asia 2024Rehab Expo 2024ISPE Singapore Affiliate Conference & Exhibition 20242024 PDA Pharmaceutical Manufacturing & Quality Conference2024 PDA Cell and Gene Pharmaceutical Products Conference 2024 PDA Aseptic Manufacturing Excellence Conference2024 PDA Aseptic Processing of Biopharmaceuticals ConferencePharma Quality Excellence Awards 20244th Annual Pharma GMP Quality Management 20243rd World ADC Asia 2024LogiPharma Asia 2024